APA (7th ed.) Citation

J, P., M, A., O, K., F, D., MK, D., JM, B., . . . RR, D. (2012). Autoimmune polyendocrine syndrome type 1: Utility of KCNRG autoantibodies as a marker of active pulmonary disease and successful treatment with rituximab. Pediatric pulmonology, 47(1), 84. https://doi.org/10.1002/ppul.21520

Chicago Style (17th ed.) Citation

J, Popler, Alimohammadi M, Kämpe O, Dalin F, Dishop MK, Barker JM, Moriarty-Kelsey M, Soep JB, and Deterding RR. "Autoimmune Polyendocrine Syndrome Type 1: Utility of KCNRG Autoantibodies as a Marker of Active Pulmonary Disease and Successful Treatment with Rituximab." Pediatric Pulmonology 47, no. 1 (2012): 84. https://doi.org/10.1002/ppul.21520.

MLA (9th ed.) Citation

J, Popler, et al. "Autoimmune Polyendocrine Syndrome Type 1: Utility of KCNRG Autoantibodies as a Marker of Active Pulmonary Disease and Successful Treatment with Rituximab." Pediatric Pulmonology, vol. 47, no. 1, 2012, p. 84, https://doi.org/10.1002/ppul.21520.